VIVOBIOT16.99

Vivo Bio Tech Limited

· Pharma & Health
AnnualQuarterly₹ Crore
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
Revenue from Operations44.946.7
Other Income0.04.8
Total Income44.951.5
Expenses
+ Employee Benefit Expense10.111.9
+ Finance Costs7.87.5
+ Depreciation & Amortisation9.39.0
Total Expenses40.942.4
EBITDA21.120.8
EBIT11.811.8
Profit
Pretax Income4.19.1
+ Current Tax1.72.1
+ Deferred Tax-0.1-0.6
Tax Expense1.51.5
Net Income2.57.6
Total Comprehensive Income2.57.6
Per Share
Basic EPS1.694.95
Diluted EPS1.514.95
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.